Cancers · 2020 · 17 citations · 37 references
MedicineOncologyPharmacologyCancer ImmunologyImmunotherapyMonoclonal AntibodiesB Cell ActivationB Cell BiologyB-cell ResponsesCancer ImmunotherapyHematologic Malignancy TherapyTyrosine Kinase InhibitorsBruton Tyrosine KinaseBruton's Tyrosine Kinase InhibitorsBtk InhibitorsChronic Lymphocytic Leukemia TherapyJak Inhibitor TherapyJak InhibitorsJanus Kinase Inhibitor TherapyJanus Kinase-stat Signaling Activation
Targeted inhibition of Bruton’s Tyrosine Kinase (BTK) with ibrutinib and other agents has become important treatment options in chronic lymphocytic leukemia, Waldenström’s Macroglobulinemia, Mantle cell lymphoma, and non-GCB DLBCL. Clinical trials combining small molecule inhibitors with monoclonal antibodies have been initiated at rapid pace, with the biological understanding between their synergistic interactions lagging behind. Here, we have evaluated the synergy between BTK inhibitors and monoclonal antibody therapy via macrophage mediated antibody dependent cellular phagocytosis (ADCP). Initially, we observed increased ADCP with ibrutinib, whilst second generation BTK inhibitors failed to synergistically interact with monoclonal antibody treatment. Kinase activity profiling under BTK inhibition identified significant loss of Janus Kinase 2 (JAK2) only under ibrutinib treatment. We validated this potential off-target effect via JAK inhibition in vitro as well as with CRISPR/Cas9 JAK2−/− experiments in vivo, showing increased ADCP and prolonged survival, respectively. This data supports inhibition of the JAK-STAT (Signal Transducers and Activators of Transcription) signaling pathway in B-cell malignancies in combination with monoclonal antibody therapy to increase macrophage-mediated immune responses.
37
Targeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic Leukemia
John C. Byrd, Richard R. Furman, Steven Coutré et al. · New England Journal of Medicine · 2013 · 2.2K citations · Full text
Medicine, Hematology, Oncology +12
Leonard D. Shultz, Bonnie Lyons, Lisa Burzenski et al. · The Journal of Immunology · 2005 · 1.7K citations · Full text
Targeting B cell receptor signaling with ibrutinib in diffuse large B cell lymphoma
Wyndham H. Wilson, Ryan M. Young, Roland Schmitz et al. · Nature Medicine · 2015 · 1.1K citations · Full text
Ibrutinib–Rituximab or Chemoimmunotherapy for Chronic Lymphocytic Leukemia
Tait D. Shanafelt, Xin V. Wang, Neil E. Kay et al. · New England Journal of Medicine · 2019 · 738 citations · Full text
Medicine, Immunology, Oncology +16